---
title: "US FDA grants R3 Vascular IDE approval for ELITE-BTK pivotal trial of Magnitude drug-eluting bioresorbable scaffold"
date: "2024-11-04T14:46:20.000Z"
publishedDate: "4 novembre 2024"
summary: "R3 Vascular today announced that the US Food and Drug Administration (FDA) has granted the company investigational device exemption (IDE) approval to initiate its ELITE-BTK pivotal trial of the next-generation Magnitude drug-eluting bioresorbable scaffold for below-the-knee (BTK) peripheral arterial disease (PAD). “We are pleased to have FDA approval for our ELITE-BTK pivotal trial, thus allowing [&#8230;] The post US FDA grants R3 Vascular IDE approval for ELITE-BTK pivotal trial of Magnitude drug-eluting bioresorbable scaffold appeared first on Vascular News ."
importance: ""
sourceUrl: "https://vascularnews.com/us-fda-grants-r3-vascular-ide-approval-for-elite-btk-pivotal-trial-of-magnitude-drug-eluting-bioresorbable-scaffold/"
tags: ["France", "Actualité", "Vascular News — Latest"]
permalink: "/papers/2024-11-04-us-fda-grants-r3-vascular-ide-approval-for-elite-btk-pivotal-trial-of-magnitude-drug-eluting-bioresorbable-scaffold"
imageUrl: "https://vascularnews.com/wp-content/uploads/sites/7/2021/05/Eric-Secemsky-web.jpg"
imageCredit: "Image de l’article — droits possiblement réservés — https://vascularnews.com/us-fda-grants-r3-vascular-ide-approval-for-elite-btk-pivotal-trial-of-magnitude-drug-eluting-bioresorbable-scaffold/"
---

![US FDA grants R3 Vascular IDE approval for ELITE-BTK pivotal trial of Magnitude drug-eluting bioresorbable scaffold](https://vascularnews.com/wp-content/uploads/sites/7/2021/05/Eric-Secemsky-web.jpg)

*Crédit image : Image de l’article — droits possiblement réservés — https://vascularnews.com/us-fda-grants-r3-vascular-ide-approval-for-elite-btk-pivotal-trial-of-magnitude-drug-eluting-bioresorbable-scaffold/*

## L’essentiel

R3 Vascular today announced that the US Food and Drug Administration (FDA) has granted the company investigational device exemption (IDE) approval to initiate its ELITE-BTK pivotal trial of the next-generation Magnitude drug-eluting bioresorbable scaffold for below-the-knee (BTK) peripheral arterial disease (PAD). “We are pleased to have FDA approval for our ELITE-BTK pivotal trial, thus allowing [&#8230;] The post US FDA grants R3 Vascular IDE approval for ELITE-BTK pivotal trial of Magnitude drug-eluting bioresorbable scaffold appeared first on Vascular News .

## Lien source

https://vascularnews.com/us-fda-grants-r3-vascular-ide-approval-for-elite-btk-pivotal-trial-of-magnitude-drug-eluting-bioresorbable-scaffold/
